“…Hepatitis C virus (HCV) was first isolated by Choo et al [19891. The subsequent application of enzyme immunoassay (EIA) for circulating antibody to HCV using recombinant antigens has made it clear that HCV accounts for most cases of blood-borne non-A, non-B hepatitis Kuo et al, 1989;Bruix et al, 1989;Alter et al, 1989;Miyamura et al, 19901, and infects about 1% of the general population worldwide [Esteban et al, 1989;Stevens et al, 1990; van der Poel 0 1994 WILEY-LISS, INC. Wu et al, 19911. Further reports from Japan revealed difference of nucleotide sequences of Japanese isolates from that of the prototype virus isolated in the United States [Kato et al, 1989;Kubo et al, 1989;Kaneko et al, 1990;Maeno et al, 1990;Takeuchi et al, 1990a,b,c;Okamoto et al, 1990Okamoto et al, , 1991Takamizawa et al, 1991;Inchauspe et al, 1991;Enomoto et al, 19901, and it was known that patients in the United States and European countries are infected mostly with prototype HCV and the type isolated from Japan infects most of the victims in Asian countries [Chen et al, 1991;Chou et al, 1991;Takada et al, 1992;Okamoto et al, 1992a,b;Houghton et al, 19911. More recently, by comparing nucleotide sequence motif of domains, six genotypes of HCV are classified, and different genotypes are known to coexist in various geographical locations [Takada et al, 1992;Okamoto et al, 1992a;Cha et al, 1992;Kato et al, 1990;Chan et al, 1991;Mori et al, 19921. Recently, two rather simplified methods were developed for genotyping of HCV depending on: 1) the amplification of a C gene sequence by polymerase chain reaction (PCR) using a universal primer and a mixture of four type-specific primers based on variation in nucleotide sequence within restricted regions in the putative C gene of HCV, and 2) identification of restriction fragment l...…”